– Extension Increases Total Addressable Market to Include Both Conventional Non-Amplifying mRNA and saRNA – – Extension Enabled by the Company’s Ongoing Platform Development and Optimization – STONY BROOK, N.Y. November 16, 2023 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, announced the expansion of its […]
Preclinical Orders for Additional Customers Underway STONY BROOK, N.Y. November 9, 2023 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced that it has successfully manufactured and shipped its first research use only quantity of self-amplifying mRNA (saRNA) template generated by its Linea™ DNA […]
Agreement Focuses on the Accelerated Development of LNP-encapsulated LineaDNA™ Vaccines to Eliminate the Use of Plasmid DNA and Reduce the Dependence on Extreme Cold Chains of Today’s mRNA Vaccines STONY BROOK, NY and ITHACA, NY / ACCESSWIRE / September 14, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (‘Applied DNA’ or the “Company”), a leader in polymerase chain […]
– Experienced Biopharma/Pharmaceutical Executive to Lead Implementation of cGMP-quality LineaDNA™ Capability for IVT mRNA Production – – Previously Led Manufacturing Operations Scale-up for the BioNTech/Pfizer mRNA COVID-19 Vaccine at CDMO Division of Maravai LifeSciences – STONY BROOK, N.Y. – September 6, 2023 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, […]
STONY BROOK, N.Y. – July 18, 2023 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA”), a leader in PCR-based DNA technologies, today announced the participation of LineaRx, Inc., its majority-owned biotherapeutics subsidiary, in upcoming mRNA industry conferences in Boston: “We are eager to introduce our newly launched Linea™ IVT platform and engage therapy developers […]
– Platform Enables Customers to Manufacture mRNA with Substantial Reduction in dsRNA and Manufacturing Complexities; Integrable into Current mRNA Workflows – – Platform Currently Available Under Early Access Program – STONY BROOK, N.Y. – July 13, 2023 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA […]
A novel approach of using a DNA therapeutic platform with a Lipid Nanoparticle (LNP)-based delivery system and focused on veterinary vaccine applications has been evaluated and our preliminary results are reported in this white paper. The studies shown herein support the advancement of high-fidelity, PCR-produced linearDNA™ in vaccine applications, taking advantage of linearDNA’s rapid design, […]
STONY BROOK, N.Y. – March 29, 2023 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced that it has established a new high bar for the production of DNA with the manufacture and shipment of a multi-gram quantity of linearDNA™ in under six weeks. The quantity was […]
The study, titled ‘A linear DNA vaccine candidate encoding the SARS-CoV-2 Receptor Binding Domain elicits protective immunity in domestic cats,’ supports the further development of the Company’s LinearDNA™ platform for the large-scale enzymatic (PCR, polymerase chain reaction) production of prophylactic and therapeutic linearDNA™-based vaccines.
– Planned Doubling of Current DNA Production Capacity will Enable Company to Support Customers from Early-stage Drug Discovery Through Late-phase Clinical Trials – – Expansion Plans Catalyzed by Growing Industry Demand for LinearDNA™, Repeat and New Proof-of-Concept Orders from Customers with Long-Term Requirements for cGMP DNA – Operational Commencement Expected in 2H CY2023 – STONY […]